Fortis Healthcare Stock Price - ₹917.50 | Healthcare Services

‌
‌
‌

Company insights, generated from the most recent coverage.

Supreme Court's Sept 2022 direction for forensic audit was triggered by systemic enforcement gaps, including asset dissipation despite status quo orders and inadequate investigation of cross-border fund flows.
Read more
Fortis shareholding dilution (70% to 5%) causally linked to Religare diversions: Singh brothers used Rs 2,315 cr loans from Religare to maintain share pledges; loan recall in 2019 triggered forced sales.
Read more
Rs 403 crore siphoned from Fortis Hospitals to RHC Holding via conduit entities (Best, Fern, Modland); SEBI ordered repayment noting funds were used to repay promoter-connected loans.
Read more

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Fortis Healthcare expands revenue and patient pricing, though rising costs and margin pressure test profitability.

Consolidated revenue grows from ₹2,166.7 Cr to ₹2,545.0 Cr from Q1 FY26 to Q1 FY27 — steady top-line expansion across hospitals and diagnostics.

Operating expenses accelerate from ₹1,676.0 Cr to ₹2,007.9 Cr from Q1 FY26 to Q1 FY27 — cost inflation outpaces revenue growth.

Average realization per patient rises from ₹878 to ₹952 from Q1 FY26 to Q1 FY27 — stronger pricing power and higher-value treatments.

Consolidated EBITDA margin contracts from 22.6% to 22.3% from Q1 FY26 to Q1 FY27 — margin compression from higher operational costs.

Diagnostics operating margin expands from 23.0% to 23.9% from Q1 FY26 to Q1 FY27 — improved efficiency and a growing direct-to-consumer base.

Cash reserves fall from ₹486 Cr to ₹347 Cr from Q1 FY26 to Q1 FY27 — tighter liquidity amid capex and debt servicing.

High-performing hospital facilities grow from 11 to 14 from Q1 FY26 to Q1 FY27 — core assets scale effectively with stable occupancy.

International payor share drops from 8.1% to 7.5% from Q2 FY26 to Q1 FY27 — weaker cross-border demand pressures revenue mix.

Net debt to EBITDA improves from 0.92x to 1.01x from Q1 FY26 to Q1 FY27 — leverage remains manageable despite ongoing capital investments.

Hospital EBITDA margin declines from 22.6% to 20.6% from Q1 FY26 to Q1 FY27 — core operations face profit squeeze despite steady bed occupancy.

‌
‌
‌

In the news

Delhi HC orders 6-month forensic audit of Singh brothers' assets

Delhi Master Plan 2047 boosts Max, Fortis, Medanta stocks

Indus Towers AGM approves FY26 financials, dividend amid institutional dissent

ICICI Securities recommends Fortis Healthcare buy at ₹1075 target

Fortis Healthcare Q1 FY27 Results: Multiple Brokerages Set ₹1100-1130 Targets

Fortis Healthcare reappoints Raghuvanshi as MD for 2 years

Fortis Healthcare partners Dion Group for 300-bed Odisha hospital

Delhi CM orders strict action against Fortis Shalimar Bagh after inquiry

Religare Broking suggests 3 stock strategies amid market volatility

Q4FY26 Turnaround Tales: Five Paths to Profitability

Mirae Asset recommends sell calls on Kalyan Jewellers, IndiGo

Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results

Medical tourism recovery stalled by West Asia conflict

79 Companies Report Q4FY26 Results Today: Mixed Performance

Gift Nifty Down: Lisa Pallavi Barbora's 3 Stock Picks for May 12

Fortis Healthcare Gets Buy Rating with ₹1,100 Target

Bit Digital Stakes 89% of ₹2,500 Cr ETH Treasury in Yield Strategy

Axis Sec recommends Samvardhana Motherson, Indusind Bank, Fortis

Fortis Launches Obesity Clinic While IHH Catalyst Accelerates Healthcare Innovation

Fortis Healthcare schedules Q3 FY26 results meeting for Feb 13

Fortis Healthcare